Baricitinib vs TNF Inhibitors in Rheumatoid Arthritis at Increased VTE Risk: Long-Term Safety, Exploratory Efficacy, and the Impact of COVID-19 on Serious Infections (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1400; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; P4 | "Adults with moderate to severe RA with a diagnosis consistent with 2010 ACR/EULAR classification criteria and ≥1 predefined VTE risk factor (prior VTE, age ≥60 years, BMI ≥30 kg/m2, or age 50-< 60 with BMI 25-< 30 kg/m2) were randomized 1:1:1 to baricitinib 2 or 4mg QD, or TNFi (adalimumab or etanercept). In active RA patients with increased VTE risk, noninferiority of baricitinib vs TNFi for VTE was not demonstrated, although the CI crossed 1. MACE and mortality were similar between groups. SIs were more frequent with baricitinib vs TNFi, largely driven by COVID-19 events."
Clinical • Genetic Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Skin Cancer • Solid Tumor • CRP
|
|
Peter Taylor1; Jeffrey Curtis2; Jon Giles3; Roy Fleischmann4; Grace Wright5; Elizabeth Perkins6; Deepak Bhatt7; Torsten Witte8; Masayoshi Harigai9; Rieke Alten10; Walter Deberdt11; Conor O'Leary11; Rodica Rosu11; Louis Sanden11; Sandra Chinchilla11; Joseph O'Shea11; Anabela Cardoso11; Burcu Ertugrul Vardar11; Natasha Troy11; Jens Gerwien11; Josef Smolen12
|